Chronic Care Policy Alliance https://validator.w3.org/feed/docs/rss2.html CCPA Responds to CMS Drug Price Negotiation Announcement (IPAY 2028) CCPA Supports Bipartisan RESULTS Act to Protect Medicare Diagnostic Testing CCPA Submits Letters to Congress Ahead of Insurance Hearings CCPA Submits Comment Letter to CMS on Proposed Interoperability Standards and Prior Authorization for Drugs rule Value Assessments Comprehensive medication management Interoperability Patient Assistance Payment Programs (Copay Accumulators) Obesity CMS and Physician Pay Pharmacy Care Access Utilization Management: Prior Authorization, Step Therapy and Non-Medical Switching Prescription Drug Affordability Boards (PDAB) Home Federal Policy Why PBM Reform Must Be a Priority in 2026 Denied — but Not Defeated: Appeals Help Patients Access Care CCPA Submits Comments on IPAY 2028 Selections CCPA Submits Comments on Proposed Medicare Drug Pricing Models What Medicare Drug Negotiation Means for Patients in 2026 and Beyond Our Work Utah Tennessee Ohio North Carolina Missouri Mississippi Massachusetts Louisiana Kentucky Indiana Illinois Colorado California Alabama CCPA Statement on Most Favored Nation CCPA Sends Comments to Congress on the Dangers of MFN Pricing Models The Hidden Middleman Affecting Your Lab Tests: What You Need to Know About Laboratory Benefit Managers (LBMs) Innovation (Multi-Cancer Early Detection Tests – MCED) 340B Drug Pricing Program Put Patients First by Studying the 340B Program RECAP: CCPA’s Washington, D.C. Advocacy Trip Pharmacy Benefit Managers (PBMs) CCPA Statement on Medicare GLOBE and GUARD Rules Webinar Recap: Drug Pricing Reform: What Patients Need to Know Energy, Insight, and Inspiration: Inside Forecast 2026 CCPA Leads Sign-On Letter Urging Congress to Reinstate Medicare Telehealth Flexibilities Webinar Recap: Medicare in Transition: Drug Pricing Negotiation, Open Enrollment Essentials, and Legislative Updates Leadership The Mass Compounded GLP-1 Market Is Harming Patients.